Many molecular targets have been identified in breast cancer: trastuzumab and lapatinib target the human epidermal growth factor receptor-2 (HER2) and are approved drugs for the treatment of metastatic breast cancer [4]. Here, ERBB2 is linked to breast carcinoma.